Lexicon Pharmaceuticals LXRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.5%+1.5pp | 99.4%+1.4pp | 99.4%+5.9pp | 99.2%+6.7pp | 98%+3.0pp | |
| Operating margin | -34.8%+534pp | -98.2%+536pp | -94.4%+3,943pp | -202.6%+5,210pp | -568.6%+7,477pp | |
| Net margin | -37.5%+531pp | -101.1%+544pp | -96.8%+4,042pp | -206.4%+5,344pp | -568%+7,809pp | |
| EBITDA margin | -34%+533pp | -97%+536pp | -93.5%+3,933pp | -201.6%+5,195pp | -566.7%+7,454pp | |
| Returns | ||||||
| Return on equity | -16%+70.1pp | -39.7%+128pp | -45.9%+90.2pp | -65.3%+29.5pp | -86.1%+16.6pp | |
| Return on assets | -9.2%+40.4pp | -20.8%+55.1pp | -26%+46.4pp | -40.3%+18.3pp | -49.6%+17.2pp | |
| Return on invested capital | -13.5%+62.9pp | -33.5%+75.4pp | -37.5%+51.5pp | -52.5%+26.3pp | -76.3%+13.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.2× | 0.2×+0.1× | 0.3×+0.3× | 0.2×+0.2× | 0.1×+0.1× | |
| Inventory turnover | 1.5×-0.2× | 1.1×— | 1.1×— | 1.3×— | 1.7×— | |
| Liquidity | ||||||
| Current ratio | 18.8×+16.6× | 4.9×-0.6× | 5.6×-1.8× | 4.2×-7.3× | 2.2×-13.4× | |
| Quick ratio | 18.8×+16.5× | 4.9×-0.6× | 5.6×-1.8× | 4.2×-7.3× | 2.2×-13.3× | |
| Cash ratio | 6.8×+6.2× | 3×+1.6× | 3.6×+2.7× | 1.4×+0.2× | 0.6×-3.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×-0.6× | 0.6×-0.1× | 0.5×-0.1× | 0.5×0.0× | 0.9×+0.5× | |
| Debt-to-assets | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.4×+0.1× | |
| Interest coverage | -3.5×+10.5× | -5.9×+9.4× | -6.8×+10.5× | -10.5×+4.9× | -14.1×+2.1× | |
| Per Share | ||||||
| Book value per share | $0.51+49.1% | $0.30-35.0% | $0.33-33.0% | $0.36-53.9% | $0.34-71.1% | |
| Valuation | ||||||
| Market capitalization | $1.02B+273% | $417.91M+56.5% | $490.59M-13.6% | $279.76M-53.9% | $166.58M-71.8% | |
| Enterprise value | $1.01B+219% | $416.82M+36.0% | $476.88M-25.4% | $290.84M-57.1% | $209.95M-65.1% | |
| Price / sales | 14.6×+5.9× | 8.4×-0.2× | 6.9×-102× | 4.8×-162× | 5.3×-250× | |
| Price / book | 5×+2.8× | 3.9×+2.1× | 4.1×+0.9× | 2.2×-0.4× | 1.4×-0.7× | |
| EV / sales | 14.5×+4.4× | 8.4×-1.5× | 6.7×-115× | 5×-181× | 6.7×-253× | |
| Earnings yield | -2.6%+62.5pp | -12%+63.0pp | -14%+24.1pp | -43.1%-9.8pp | -106.4%-73.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Lexicon Pharmaceuticals's profit margins?
- Lexicon Pharmaceuticals (LXRX) runs a 99.5% gross margin and a -34.8% operating margin, with a -37.5% net margin.
- Where do Lexicon Pharmaceuticals's ratios come from?
- Every ratio is computed from Lexicon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
